SCHEMBL12463204

SCHEMBL12463204

CCOC(=O)Nc1cccc(Cn2nc(-c3cc(F)c(OCCCN(C)C)c(F)c3)ccc2=O)c1

nearest known ligand 0.76

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
MET P08581 20/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12463189 0.98 MET (0.72) MET
SCHEMBL12462923 0.96 MET (0.72) MET
SCHEMBL12462918 0.93 MET (0.68) MET
SCHEMBL12462944 0.91 MET (0.74) MET
SCHEMBL12462919 0.91 MET (0.74) MET
SCHEMBL12463187 0.91 MET (0.73) MET
SCHEMBL12463191 0.91 MET (0.73) MET
SCHEMBL12462914 0.91 MET (0.73) MET
SCHEMBL12462933 0.90 MET (0.75) MET
SCHEMBL12463383 0.90 MET (0.63) MET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8445489-B2 Aryl ether pyridazinone derivatives MERCK PATENT GMBH (DE) 2013-05-21 US disclosed
US-8445489-B2 Aryl ether pyridazinone derivatives MERCK PATENT GMBH (DE) 2013-05-21 US disclosed
EP-2152370-B1 ARYL ETHER PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2011-07-06 EP disclosed
US-20100179149-A1 ARYL ETHER PYRIDAZINONE DERIVATIVES MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2010-07-15 US disclosed
US-20100179149-A1 ARYL ETHER PYRIDAZINONE DERIVATIVES MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2010-07-15 US disclosed
WO-2008145242-A1 ARYL ETHER PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2008-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179149-A1 ARYL ETHER PYRIDAZINONE DERIVATIVES MET, RET, ERBB2 MET 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.